Immuno-Oncology and Technology: Volume 1 to Volume 4 2019 PDF

4 $

Immuno-Oncology and Technology: Volume 1 to Volume 4

Title: IOTECH: Advancing Immuno-Oncology Research and Technology

Introduction: IOTECH, the sister journal to Annals of Oncology and ESMO Open, is the latest addition to the European Society for Medical Oncology’s esteemed portfolio of world-class journals. By publishing high-quality original research articles, reviews, perspectives, technology explained papers, letters to the editor, and editorials, IOTECH serves as a prominent forum for leading experts in the field of Immuno-Oncology.

Scope and Aims: IOTECH is a quarterly publication led by Editor-in-Chief, Professor John Haanen, along with an international team of expert Editors and Editorial Board members. The journal publishes pre-clinical and clinical studies that delve into the natural and therapy-induced innate and adaptive immune responses against solid and hematological cancers. Furthermore, IOTECH has a strong emphasis on technological advancements in Immuno-Oncology, striving to showcase cutting-edge developments that decipher and improve clinical outcomes.

Research and Technology Focus: IOTECH prioritizes high-quality original research in Immuno-Oncology, encompassing studies on the immune system’s response to various cancer types. The journal aims to foster a deeper understanding of natural and induced immune responses to solid tumors and hematological malignancies, ultimately advancing the field’s knowledge and potential therapeutic strategies.

Technological Advancements: A distinguishing feature of IOTECH is its spotlight on technological developments in Immuno-Oncology. The journal seeks to highlight breakthroughs that contribute to deciphering the complex interactions between the immune system and cancer cells. By showcasing innovations that enhance clinical outcomes, IOTECH plays a pivotal role in driving progress in Immuno-Oncology.

Global Collaboration and Expertise: With its prestigious editorial team and international board of expert members, IOTECH serves as a hub for collaboration among today’s leading figures in Immuno-Oncology research and technology. The journal’s contributions to scientific exchange and knowledge dissemination facilitate impactful advancements in the field.

Conclusion: IOTECH stands as a vital platform for the dissemination of high-quality research in Immuno-Oncology and technological innovations that improve clinical outcomes. With its esteemed editorial leadership and dedication to promoting the latest research in this rapidly evolving field, IOTECH plays a pivotal role in shaping the future of Immuno-Oncology and its potential to revolutionize cancer treatment worldwide.